Compare Diamondback Energy Inc (FANG) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diamondback Energy Inc vs Novartis AG — how do they compare? Diamondback Energy Inc trades at $192.03 (market cap $53.67B), while Novartis AG trades at $143.75 (market cap $268.57B). The key difference: Novartis AG is far larger — about 5× Diamondback Energy Inc's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Diamondback Energy Inc for 69 Days and Novartis AG for 82 Days on average.
| FANG | NVS | |
|---|---|---|
Market Cap | $53.67B | $268.57B |
Volume | 2,250,644 | 1,532,573 |
Sector | Energy | Health |
52-Week High | $213.69 | $168.62 |
52-Week Low | $137.29 | $121.80 |
Typical Hold Time | 69 Days | 82 Days |
Enterprise Value | $65.83B | $309.89B |
Dividend Yield | 2.3% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diamondback Energy (FANG) trades at $192.13, up 4.2% in the last session, with a bullish technical signal and strong analyst support. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains solid cash flow from operations. Revenue growth is robust, with 2025 revenue reaching $14.93 billion, though net income margins have compressed. A dividend of $1.10 is scheduled for August 2026, and institutional interest remains high.
The outlook is positive with a consensus price target of $231.77, implying 20% upside. Risks include volatile oil prices and insider selling, but strong Permian Basin positioning and efficient operations support growth. Earnings on November 2, 2026, will be critical for near-term momentum.
Novartis (NVS) trades at $143.75, up 0.33% on the day, near the consensus price target of $146.00. Recent earnings show mixed quarterly beats and a miss in Q1 2026, with revenue growth to $56.67B in 2025 and a net income margin of 24.67%. Technical indicators signal a bearish trend, while analyst sentiment is mixed with 24% buy ratings. The company recently announced a $7.8B licensing deal with China's Abogen for mRNA therapy, but faces scrutiny over clinical setbacks and M&A strategy.
The outlook for NVS hinges on execution of its pipeline and deal integration amid investor caution. Opportunities include expansion into autoimmune treatments and solid profitability, but risks involve trial failures, regulatory probes, and debt levels rising to 30.26% of assets. Wall Street remains neutral with a slight upside to the price target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
